Earnings Summary

Alpine Immune Sciences Inc’s revenue fell -25.09% since last year same period to $7.03Mn in the Q1 2024. On a quarterly growth basis, Alpine Immune Sciences Inc has generated -77.21% fall in its revenue since last 3-months.

Alpine Immune Sciences Inc’s net profit fell -62.74% since last year same period to $-17.92Mn in the Q1 2024. On a quarterly growth basis, Alpine Immune Sciences Inc has generated -400.64% fall in its net profits since last 3-months.

Alpine Immune Sciences Inc’s net profit margin fell -117.25% since last year same period to -254.81% in the Q1 2024. On a quarterly growth basis, Alpine Immune Sciences Inc has generated -1419.05% fall in its net profit margins since last 3-months.

Alpine Immune Sciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.42 - a -2.44% fall from last quarter’s estimates.

Alpine Immune Sciences Inc’s earning per share (EPS) estimates for the current year stand at -0.42.

Alpine Immune Sciences Inc’s earning per share (EPS) jumped 0% since last year same period to -0.28 in the Q1 2024. This indicates that the Alpine Immune Sciences Inc has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Alpine Immune Sciences Inc’s return on assets (ROA) stands at -0.1.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Alpine Immune Sciences Inc’s return on equity (ROE) stands at -0.15.